ESPERION THERAPEUTICS INC (ESPR)

Company Profile

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The company is headquartered in Vero Beach, Florida and currently employs 240 full-time employees. The company went IPO on 2013-06-24. The firm is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The firm's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The firm's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi.

Company Info

ESPERION THERAPEUTICS INC

601 21St Street, Suite 300

Vero Beach FLORIDA 48108

P: 17724532770

CEO: Tim M. Mayleben

Employees: 240

Website: https://www.esperion.com/